Mesoblast Ltd has released a press release.
Phase 3 Heart Failure Trial Size Substantially Reduced
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Mesoblast
- US Govt Grants for Further Development of Stem Cell Products
- USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion
- Type 2 Diabetes Trial Results Published In Diabetes Care
- Strategic Update and Q1 Financial Results Presentation
- Rheumatoid Arthritis New Major Clinical Target for MSB
Later from Mesoblast
- MSB Therapy Shows Benefit In First Cohort Of RA Patients
- Half Yearly Report and Accounts (including Appendix 4D)
- Increased Survival Using MSB Cells In Children With aGVHD
- GVHD Product Launched In Japan
- Key US Patent Granted For Treatment Of Rheumatoid Arthritis
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast